(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 October 2020 (01.10.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/198268 A1

(51) International Patent Classification:
*A61K 31/7125* (2006.01) *A61P 43/00* (2006.01)
*A61P 21/00* (2006.01) *A61K 9/00* (2006.01)

(21) International Application Number:
PCT/US2020/024550

(22) International Filing Date:
25 March 2020 (25.03.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/825,573 28 March 2019 (28.03.2019) US
62/902,518 19 September 2019 (19.09.2019) US

(71) Applicant: **SAREPTA THERAPEUTICS, INC.** [US/US]; 215 First Street, Cambridge, MA 02142 (US).

(72) Inventor: **KAYE, Edward, M.**; c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US).

(74) Agent: **VERNI, Christopher** et al.; Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *of inventorship (Rule 4.17(iv))*

**Published:**
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: METHODS FOR TREATING MUSCULAR DYSTROPHY WITH CASIMERSEN

(57) Abstract: The present disclosure provides, among other things, improved compositions and methods for treating muscular dystrophy. For example, the disclosure provides methods for treating Duchenne muscular dystrophy patients having a mutation in the DMD gene that is amenable to exon 45 skipping by administering an effective amount of casimersen.

WO 2020/198268 A1